Aim: Research and innovation (R&I) actors are fundamental in shortening the translational gap of personalized medicine in health systems. In the context of the ‘Integrating China in the International Consortium for Personalized Medicine’ project, we aimed to map the current landscape of R&I actors in the field of personalized medicine in the EU and China. Methods: A two-phase desk research study was conducted. Results: We identified 78 R&I actors. Research and technology organizations were the most frequent in both the EU and China. The identified R&I actors were active in a wide range of fields. The EU and China have many different R&I actors addressing personalized medicine-related issues, with few characteristics in common. Conclusion: More efforts are needed to ensure these R&I actors are encouraged to work together to bridge each other’s gaps.
Causio, F. A., Hoxhaj, I., Beccia, F., Di Marcantonio, M., Strohäker, T., Cadeddu, C., Ricciardi, W., Boccia, S., Research and innovation in personalized medicine: a descriptive synthesis of actors in the EU and China, <<PERSONALIZED MEDICINE>>, 2023; 20 (3): 227-238. [doi:10.2217/pme-2023-0003] [https://hdl.handle.net/10807/277223]
Research and innovation in personalized medicine: a descriptive synthesis of actors in the EU and China
Causio, Francesco Andrea;Hoxhaj, IldaWriting – Original Draft Preparation
;Beccia, Flavia
Writing – Original Draft Preparation
;Di Marcantonio, MarziaWriting – Original Draft Preparation
;Cadeddu, ChiaraWriting – Review & Editing
;Ricciardi, WalterSupervision
;Boccia, StefaniaSupervision
2023
Abstract
Aim: Research and innovation (R&I) actors are fundamental in shortening the translational gap of personalized medicine in health systems. In the context of the ‘Integrating China in the International Consortium for Personalized Medicine’ project, we aimed to map the current landscape of R&I actors in the field of personalized medicine in the EU and China. Methods: A two-phase desk research study was conducted. Results: We identified 78 R&I actors. Research and technology organizations were the most frequent in both the EU and China. The identified R&I actors were active in a wide range of fields. The EU and China have many different R&I actors addressing personalized medicine-related issues, with few characteristics in common. Conclusion: More efforts are needed to ensure these R&I actors are encouraged to work together to bridge each other’s gaps.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.